respiratory system
|
• lymphocytes in the lung in doxycycline-treated transgenic mice
• clustered inflammatory cells within lymphocytic nodules, within the parenchyma, and adjacent to the pleural surface
• varying degrees of inflammation in untreated transgenic mice, but overall much less pronounced than in doxycycline-treated transgenic mice
|
|
• enlarged airspace throughout the lung in transgenic mice treated with doxycycline
• tend to be more pronounced adjacent to lymphoid aggregates
• significant increases in linear intercept in transgenic mice treated with doxycycline for 1-9 months
• significant airspace enlargement at 11-12 months of age in untreated transgenic mice
|
|
• some fibrotic lesions in transgenic mouse treated with doxycycline for 6 months
• most commonly adjacent to airways
|
immune system
|
• modest increases in the number of neutrophils recovered in lavage fluid (6% of total cells) in doxycycline-treated transgenic mice
|
|
• modest increases in the number of lymphocytes recovered in lavage fluid (2% of total cells) in doxycycline-treated transgenic mice
|
|
• dendritic cells on the periphery of lymphoid nodules as shown by CD11c immunostaining in doxycycline-treated transgenic mice
|
|
• large numbers of B lymphocytes within lymphoid nodules in transgenic mice administered doxycycline for 1-2 months as shown by B220 immunostaining
|
|
• T cell-rich zones in some lymphoid nodules as shown by CD3 immunostaining in doxycycline-treated transgenic mice
|
|
• increased CD8-positive cells within the lung parenchyma in the transgenic mice administered doxycycline for 1-2 months
|
|
• CD4-positive cells in some nodules but no CD8-positive cells in doxycycline-treated transgenic mice
|
|
• lymphocytic nodules and enlarged airspaces in the lung of transgenic mice treated with doxycycline for 1 month
• significantly higher number of lymphocytic nodules in doxycycline treated transgenic mice than in untreated transgenic mice
• small to medium sized lymphocytic nodule but normal airspaces in some untreated transgenic mouse of same age
• no inflammatory nodules observed in nontransgenic mice
|
|
• lymphocytes in the lung in doxycycline-treated transgenic mice
• clustered inflammatory cells within lymphocytic nodules, within the parenchyma, and adjacent to the pleural surface
• varying degrees of inflammation in untreated transgenic mice, but overall much less pronounced than in doxycycline-treated transgenic mice
|
hematopoietic system
|
• modest increases in the number of neutrophils recovered in lavage fluid (6% of total cells) in doxycycline-treated transgenic mice
|
|
• modest increases in the number of lymphocytes recovered in lavage fluid (2% of total cells) in doxycycline-treated transgenic mice
|
|
• dendritic cells on the periphery of lymphoid nodules as shown by CD11c immunostaining in doxycycline-treated transgenic mice
|
|
• large numbers of B lymphocytes within lymphoid nodules in transgenic mice administered doxycycline for 1-2 months as shown by B220 immunostaining
|
|
• T cell-rich zones in some lymphoid nodules as shown by CD3 immunostaining in doxycycline-treated transgenic mice
|
|
• increased CD8-positive cells within the lung parenchyma in the transgenic mice administered doxycycline for 1-2 months
|
|
• CD4-positive cells in some nodules but no CD8-positive cells in doxycycline-treated transgenic mice
|


Analysis Tools